Track SOPHiA GENETICS SA Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

SOPHiA GENETICS SA Ordinary Shares SOPH Open SOPHiA GENETICS SA Ordinary Shares in new tab

5.04 USD
EPS
-1.17
P/B
6.83
ROE
-110.00
Beta
1.14
Target Price
7.67 USD
SOPHiA GENETICS SA Ordinary Shares logo

SOPHiA GENETICS SA Ordinary Shares

🧾 Earnings Recap – Q3 2025

SOPHiA GENETICS delivered a strong Q3 2025 performance with 23% year-over-year revenue growth, driven by record new customer signings and sustained momentum in the U.S. market, prompting the company to raise its revenue guidance for the year.

  • New customer signings reached 31 in Q3, bringing the total for 2025 to 94, surpassing last year’s total.
  • U.S. revenue grew 30% year-over-year as new strategic partnerships with major health systems were established.
  • The launch and global adoption of the liquid biopsy application MSK-ACCESS has seen more than 60 customers signed, with significant backing from AstraZeneca for its deployment.
  • SOPHiA's innovative Digital Twins technology aims to enhance treatment decision-making by leveraging multimodal data for oncology.
  • Full-year revenue guidance is now set between $75 million and $77 million, reflecting strong business momentum.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
EPS-1.17
Book Value0.69
Price to Book6.83
Debt/Equity133.67
% Insiders6.798%
Growth
Revenue Growth0.22%
Estimates
Forward P/E-8.39
Forward EPS-0.56
Target Mean Price7.67

DCF Valuation

Tweak assumptions to recompute fair value for SOPHiA GENETICS SA Ordinary Shares (SOPH)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

SOPHiA GENETICS SA Ordinary Shares Logo SOPHiA GENETICS SA Ordinary Shares Analysis (SOPH)

Switzerland Health Care Official Website Stock

Is SOPHiA GENETICS SA Ordinary Shares a good investment? SOPHiA GENETICS SA Ordinary Shares (SOPH) is currently trading at 5.04 USD. Market analysts have a consensus price target of 7.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: SOPHiA GENETICS SA Ordinary Shares is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is -0.56.

Investor FAQ

Does SOPHiA GENETICS SA Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is SOPHiA GENETICS SA Ordinary Shares?

SOPHiA GENETICS SA Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of -1.17.

Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Exchange Ticker
NMS (United States) SOPH

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion